Advertisement
Loading...

biote Corp.

BTMDNASDAQ
Healthcare
Medical - Care Facilities
$1.90
$-0.17(-8.44%)
U.S. Market is Open • 12:42
Advertisement

biote Corp. Fundamental Analysis

biote Corp. (BTMD) shows weak financial fundamentals with a PE ratio of 3.91, profit margin of 8.29%, and ROE of -22.91%. The company generates $0.3B in annual revenue with weak year-over-year growth of -2.52%.

Key Strengths

PEG Ratio-0.13

Areas of Concern

ROE-22.91%
We analyze BTMD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 28.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
28.0/100

We analyze BTMD's fundamental strength across five key dimensions:

Efficiency Score

Excellent

BTMD demonstrates superior asset utilization.

ROA > 10%
17.53%

Valuation Score

Excellent

BTMD trades at attractive valuation levels.

PE < 25
3.91
PEG Ratio < 2
-0.13

Growth Score

Weak

BTMD faces weak or negative growth trends.

Revenue Growth > 5%
-2.52%
EPS Growth > 10%
8.34%

Financial Health Score

Excellent

BTMD maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.93
Current Ratio > 1
1.29

Profitability Score

Weak

BTMD struggles to sustain strong margins.

ROE > 15%
-2290.62%
Net Margin ≥ 15%
8.29%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BTMD Expensive or Cheap?

P/E Ratio

BTMD trades at 3.91 times earnings. This suggests potential undervaluation.

3.91

PEG Ratio

When adjusting for growth, BTMD's PEG of -0.13 indicates potential undervaluation.

-0.13

Price to Book

The market values biote Corp. at -1.09 times its book value. This may indicate undervaluation.

-1.09

EV/EBITDA

Enterprise value stands at -0.43 times EBITDA. This is generally considered low.

-0.43

How Well Does BTMD Make Money?

Net Profit Margin

For every $100 in sales, biote Corp. keeps $8.29 as profit after all expenses.

8.29%

Operating Margin

Core operations generate 16.99 in profit for every $100 in revenue, before interest and taxes.

16.99%

ROE

Management delivers $-22.91 in profit for every $100 of shareholder equity.

-22.91%

ROA

biote Corp. generates $17.53 in profit for every $100 in assets, demonstrating efficient asset deployment.

17.53%

Following the Money - Real Cash Generation

Operating Cash Flow

biote Corp. produces operating cash flow of $46.96M, showing steady but balanced cash generation.

$46.96M

Free Cash Flow

biote Corp. generates strong free cash flow of $41.29M, providing ample flexibility for dividends, buybacks, or growth.

$41.29M

FCF Per Share

Each share generates $0.94 in free cash annually.

$0.94

FCF Yield

BTMD converts 32.69% of its market value into free cash.

32.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

3.91

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.13

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.09

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.47

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.93

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.29

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.23

vs 25 benchmark

ROA

Return on assets percentage

0.18

vs 25 benchmark

ROCE

Return on capital employed

0.53

vs 25 benchmark

How BTMD Stacks Against Its Sector Peers

MetricBTMD ValueSector AveragePerformance
P/E Ratio3.9129.06 Better (Cheaper)
ROE-22.91%733.00% Weak
Net Margin8.29%-53111.00% (disorted) Weak
Debt/Equity-1.930.38 Strong (Low Leverage)
Current Ratio1.294.02 Neutral
ROA17.53%-19397.00% (disorted) Strong

BTMD outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews biote Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-60.07%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-77.55%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-67.75%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ